In:
Oncology, S. Karger AG, Vol. 57, No. 2 ( 1999), p. 157-163
Abstract:
Expression of the proto-oncogene c- 〈 i 〉 myc 〈 /i 〉 has been implicated in liver regeneration and hepatocarcinogenesis. The biologic significance of c- 〈 i 〉 myc 〈 /i 〉 gene amplification in human hepatocellular carcinoma, however, is unconfirmed. We correlated c- 〈 i 〉 myc 〈 /i 〉 gene amplification with clinicopathologic features, proliferative activity, and p53 expression in 42 resected tumors. c- 〈 i 〉 myc 〈 /i 〉 amplification in tumor tissue was determined using a differential polymerase chain reaction, a useful procedure for the evaluation of gene amplification in archival formalin-fixed paraffin-embedded tissues, in comparison with a dopamine D2 receptor gene. Proliferative activity was estimated by numbers of argyrophilic nucleolar organizer regions and immunohistochemical nuclear labeling rates using a monoclonal antibody against Ki-67. The c- 〈 i 〉 myc 〈 /i 〉 gene was amplified in 14 of 42 tumors (33.3%). Amplification of c- 〈 i 〉 myc 〈 /i 〉 was more frequent in younger patients and in larger tumors, and less differentiated tumors. No correlation was noted with α-fetoprotein level or viral hepatitis state. The amplification showed positive correlation with both proliferative activity and p53 overexpression. Disease-free survival in patients showing c- 〈 i 〉 myc 〈 /i 〉 amplification was significantly shorter than in those without amplification. These results suggest that c- 〈 i 〉 myc 〈 /i 〉 amplification is an indicator of malignant potential and poor prognosis in hepatocellular carcinoma. c- 〈 i 〉 myc 〈 /i 〉 amplification and p53 alteration may be coparticipating events in the progression of these tumors.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
1999
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Bookmarklink